Pharmaceuticals

Takeda seeks FDA approval for its gut-focused drug ENTYVIO in children, a major step toward a new era of treatment for the rising tide of pediatric IBD.

A novel TYK2 inhibitor that can enter the central nervous system has begun human trials, signaling a new frontier for treating diseases like MS and lupus.

New long-term data for masitinib shows a near doubling of 5-year survival for ALS patients, with many maintaining quality of life. Is this the turning point?

An industry award for TraceLink's OPUS platform signals a pivotal shift from passive automation to active AI 'agents' managing our most critical logistics.

A new biologic, Nucala, gains Health Canada approval for a specific type of COPD, offering hope for patients and a new strategic frontier for GSK.

A survey reveals 75% of lab researchers prioritize peptide quality over price, a clear signal against the backdrop of a scientific reproducibility crisis.

Dana-Farber's historic $50M Yawkey grant funds more than a building; it fuels a new era of integrated research and patient-centric cancer treatment.

A market poised for 31% annual growth signals a new era for Alcohol-associated Liver Disease. As pharma chases a cure, a new class of drugs emerges.

A Phase 1 trial launch is more than a milestone; it's a look at the future of pharma, where AI-driven speed and strategic global partnerships converge.

Matisse Pharmaceuticals' new sepsis drug just got a major boost from the FDA. But the real story is the invisible infrastructure—both biological and regulatory—it aims to master.

Enveric Biosciences heads to a key UBS investor day to pitch its non-hallucinogenic antidepressant, EB-003. Can it secure the capital needed to revolutionize CNS?

Quantified's new platform promises a future of continuous, compliant sales coaching. It's not just training; it's a bid to become the system of record.

A $20M round for CELYSTRA Pharma isn't just a launch; it's a strategic maneuver to solve Canada's rare disease gap and redefine Québec's role in the market.

Phase 2a data shows a new drug not only stops bone-destroying cancer but heals the damage, with no adverse events. This is a strategic game-changer.

A new fellowship award spotlights how chronic stress rewrites our immune system, pointing to a future where we might reverse a key driver of aging.

With a novel 'gastric bypass in a pill' and a new CFO known for orchestrating lucrative exits, Syntis Bio is gearing up for a high-stakes battle in the booming obesity drug market.

We map digital grids and autonomous routes, but what about the biological networks that define half of humanity? An Indian brand is using ancient wisdom to build new infrastructure for women's health.

As corporate giants swallow local clinics, one alliance offers a lifeline. Here’s how AllyGPO and BioCareSD use AI and service to help doctors stay independent.

EVERSANA poaches Takeda's Jen Norton to lead a new tech-first unit, signaling a high-stakes bid to dominate the complex life sciences access market.

A new clinical trial for a twice-yearly COPD injection could disrupt a multi-billion dollar market, offering hope to millions and validating a novel biotech strategy.